Cost Utility Analysis in Recurrent Ovarian Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00813254 |
Recruitment Status
:
Withdrawn
First Posted
: December 23, 2008
Last Update Posted
: April 19, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The goal of this research study is to learn about the quality of life and sexual functioning of women with platinum-resistant ovarian cancer as they receive other treatments for the disease.
Researchers will study the costs for chemotherapy treatments, other medical expenses, and treatment-related expenses that are not medical. Researchers will also review any symptoms these patients may experience related to the cancer or treatment.
In addition, researchers want to learn if and how these patients' caregivers feel the status of these patients' health may have affected the caregivers' productivity at work and at home.
Condition or disease | Intervention/treatment |
---|---|
Ovarian Cancer | Behavioral: Questionnaire |

Study Type : | Observational |
Actual Enrollment : | 0 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Quality of Life and Cost Utility Analysis in the Treatment of Recurrent, Platinum-Resistant Ovarian Cancer |
Study Start Date : | December 2008 |
Actual Primary Completion Date : | January 2011 |
Actual Study Completion Date : | January 2011 |

Group/Cohort | Intervention/treatment |
---|---|
Questionnaire
Longitudinal measure of QOL, sexual functioning and symptoms in women with recurrent, platinum-resistant ovarian cancer receiving multiple second-line treatment regimens
|
Behavioral: Questionnaire
Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
Other Name: Survey
|
- Mean Score for the FACT-O instrument [ Time Frame: First 2 days of chemotherapy cycles ]Participants will complete questionnaires 1 - 5 at baseline and Day 1 of each of their chemotherapy cycles.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients with recurrent, platinum-resistant epithelial ovarian cancer who are beginning any second-line treatment
- Patients must be English-speaking
- Patients must be able to read and write English
- Patients receiving all chemotherapy at MD Anderson Cancer Center
Exclusion Criteria:
- Patients with non-epithelial ovarian cancers including sex-cord stromal tumors, germ cell tumors, low-grade tumors, and metastatic disease to the ovary
- Patients who are receiving protocol therapy
- Patients who have had a prior diagnosis of invasive cancer at other sites (excluding basal cell carcinoma of the skin)
- Patients who are receiving radiation therapy as a treatment modality

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00813254
United States, Texas | |
UT MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Michael M Frumovitz, MD | M.D. Anderson Cancer Center |
Additional Information:
Responsible Party: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00813254 History of Changes |
Other Study ID Numbers: |
2007-0611 |
First Posted: | December 23, 2008 Key Record Dates |
Last Update Posted: | April 19, 2012 |
Last Verified: | April 2012 |
Keywords provided by M.D. Anderson Cancer Center:
Platinum-Resistant Ovarian Cancer Platinum-based chemotherapy Ovarian Cancer Ovary Epithelial ovarian cancer |
Quality of Life Cost Utility Analysis Sexual functioning Questionnaire Caregiver |
Additional relevant MeSH terms:
Ovarian Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases |
Genital Diseases, Female Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases Gonadal Disorders |